Mega-Trials in Heart Failure: Effects of Dilution in Examination of New Therapies
Article 2020 en
Authors
BD
Beth A. Davison
KT
Koji Takagi
SS
Stefanie Senger
Abstract
1 min read
The selection of more positive Phase 2 trials for further development does not explain the failure of HFpEF and acute HF medicine development. Increasing sample size may lead to reduced event rates and smaller treatment effects, resulting in a high rate of neutral Phase 3 trials.
Olga Milo Cotter, Beth A. Davison, Gary G. Koch, Stefanie Senger, Marco Metra, Adriaan A. Voors, Alexandre Mebazza, Olav Wendelboe Nielsen, Ovidiu Chioncel, Peter S. Pang, Barry Greenberg, Aldo Maggioni, Naoki Sato, John R. Teerlink, Gad Cotter
Michele Senni, Walter J. Paulus, Antonello Gavazzi, Alan G. Fraser, Javier Dı́ez, Scott D. Solomon, O A Smiseth, Marco Guazzi, Carolyn S.P. Lam, Aldo Maggioni, Carsten Tschöpe, Marco Metra, Soctt L. Hummel, Frank Edelmann, Giuseppe Ambrosio, Andrew J.S. Coats, Gerasimos Filippatos, M Gheorghiade, Stefan D. Anker, Daniel Levy, Marc A. Pfeffer, Wendy Gattis Stough, Burkert Pieske
Daniel Pham, Mingming Yang, Arzu Kalaycı, Alan Henderson, Inder S. Anand, Akshay S. Desai, Aldo Maggioni, Felipe A. Martínez, Marc A. Pfeffer, Jean L. Rouleau, Karl Swedberg, Muthiah Vaduganathan, Dirk van Veldhuisen, Faı̈ez Zannad, Michael R. Zile, Milton Packer, Adel R. Rizkala, Pardeep S. Jhund, Scott D. Solomon, John J.V. McMurray
Lum Kastrati, Hamidreza Raeisi‐Dehkordi, Erand Llanaj, Hugo G. Quezada‐Pinedo, Farnaz Khatami, Noushin Sadat Ahanchi, Adea Llane, Renald Meçani, Taulant Muka, John P A Ioannidis
Discussion(0)
No comments yet. Be the first to comment.